ALTIMMUNE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.01 USD | -10.00% |
|
+10.94% | -28.80% |
| May. 09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000 | MT |
Chart calendar Altimmune, Inc.
b08f62109d7c666dcb7.0iEyOT05ANwjS07gq1L60tCZBXM5fdLgkCnFZuHTHbw.mhQfb2xuaqpLASPVmGaD4rH_MAYMOKiy_22XJ76kaP3nQkZ0U3dotE8mCw~9049f6dd3356158f4a6dfb543ac1ceda
Upcoming events on Altimmune, Inc.
Past events on Altimmune, Inc.
| 2024-05-16 01:30 pm | GLP-1 Based Therapeutics Summit - Attaining Product Differentiation through Improved Patient Segment |
| 2024-05-15 10:00 am | GLP-1 Based Therapeutics Summit - Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disea |
| 2024-05-14 09:00 am | Citizens JMP Life Sciences Conference |
| 2024-05-09 08:30 am | Q1 2024 Earnings Call |
| 2024-05-09 07:00 am | Q1 2024 Earnings Release |
| 2024-05-08 04:00 pm | BTIG Obesity Health Forum |
| 2024-04-02 01:52 pm | Investor Meeting - Jefferies |
| 2024-03-27 08:30 am | Q4 2023 Earnings Call |
| 2024-03-27 07:00 am | Q4 2023 Earnings Release |
| 2024-01-05 | NASH-TAG Conference - Abstract No: #51 |
| 2023-12-01 08:30 am | MOMENTUM Phase 2 Trial Results Call |
| 2023-11-07 08:30 am | Q3 2023 Earnings Call |
| 2023-11-07 07:00 am | Q3 2023 Earnings Release |
| 2023-10-25 03:00 pm | H.C. Wainwright NASH Investor Conference - Fireside Chat |
| 2023-10-24 10:00 am | H.C. Wainwright NASH Investor Conference |
| 2023-10-03 10:30 am | European Association for the Study of Diabetes Meeting |
| 2023-09-28 08:30 am | Annual General Meeting |
| 2023-09-13 01:35 pm | Morgan Stanley Global Healthcare Conference - Fireside Chat |
| 2023-09-06 03:45 pm | Wells Fargo Healthcare Conference - Fireside Chat |
| 2023-08-10 08:30 am | Q2 2023 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 5,80 5,98 -2.92% | 8,19 7,71 6.13% | 4,41 1,18 274.08% | -0,07 0,05 -241.67% | 0,43 0,34 24.04% | 31,3 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -96,4 -92,2 -4.51% | -87,9 -89,3 1.53% | 0,00 -83,1 - | -95,4 |
|
EBIT Million USD | Released Forecast Spread | -21,5 -21,3 -0.68% | -54,8 -70,4 22.11% | -85,5 -97,5 12.28% | -87,7 -91,4 3.99% | -83,5 -93,9 11.09% | -61,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -20,6 -20,4 -0.68% | -54,5 -69,9 22.08% | -97,1 -99,3 2.24% | -84,9 -91,2 6.88% | -88,4 -81,2 -8.96% | -49,1 |
|
Net income Million USD | Released Forecast Spread | -20,5 -20,4 -0.69% | -49,0 -64,3 23.74% | -97,1 -98,7 1.64% | -84,7 -90,9 6.82% | -88,4 -81,1 -9.1% | -59,1 |
|
EPS USD | Released Forecast Spread | -1,60 -1,52 -5.26% | -1,91 -2,59 26.3% | -2,35 -2,41 2.62% | -1,81 -2,04 11.09% | -1,66 -1,47 -13.18% | -0,84 |
| Announcement Date | 27/03/20 | 25/02/21 | 15/03/22 | 28/02/23 | 27/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,03 0,88 -96.38% | 0,01 0,87 -99.08% | 0,00 1,04 -99.81% | -0,11 0,03 -423.53% | 0,02 0,00 - | 0,01 0,00 100% | 0,36 0,00 41993.02% | 0,04 0,00 1628.97% | 0,01 0,00 - | 0,00 | 31,3 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -19,4 -17,9 -8.27% | -20,3 -20,9 2.67% | -24,9 -23,9 -4.15% | -23,3 -24,8 6.18% | -21,4 -23,9 10.45% | -17,5 -21,7 19.35% | -22,0 -18,1 -21.48% | -19,4 | -21,8 | -19,9 | -20,4 | -20,9 | ||
|
EBIT Million USD | Released Forecast Spread | -19,5 -24,1 19.1% | -20,4 -22,5 9.36% | -24,8 -23,8 -3.97% | -23,1 -26,3 12.07% | -21,8 -24,8 12.15% | -18,0 -24,3 25.94% | -22,5 -22,6 0.37% | -21,2 -34,9 39.23% | -26,8 -23,7 -13.28% | -25,2 | 15,3 | -25,1 | -28,2 | -32,9 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -19,4 -24,1 19.38% | -20,1 -21,5 6.48% | -23,7 -23,8 0.4% | -21,7 -27,1 20.2% | -20,1 -24,6 18.35% | -16,1 -23,5 31.54% | -20,7 -21,6 4.4% | -31,6 -24,4 -29.94% | -24,4 -22,9 -6.37% | -24,2 | 24,4 | -24,5 | -25,7 | -30,4 |
|
Net income Million USD | Released Forecast Spread | -19,4 -24,1 19.38% | -20,1 -21,8 7.82% | -23,5 -23,4 -0.51% | -21,7 -27,1 19.97% | -20,1 -24,5 18.02% | -16,1 -16,3 1.52% | -20,7 -21,5 3.79% | -31,6 -24,3 -30.25% | -24,4 -22,8 -7.1% | -24,8 | 15,6 | -25,3 | -25,7 | -30,4 |
|
EPS USD | Released Forecast Spread | -0,44 -0,59 24.79% | -0,42 -0,50 15.15% | -0,48 -0,49 2.83% | -0,44 -0,54 18.22% | -0,40 -0,48 16.67% | -0,32 -0,45 29.41% | -0,39 -0,42 6.4% | -0,54 -0,38 -44% | -0,34 -0,36 5.99% | -0,35 | 0,19 | -0,35 | -0,34 | -0,35 |
| Announcement Date | 12/05/22 | 11/08/22 | 10/11/22 | 28/02/23 | 11/05/23 | 10/08/23 | 07/11/23 | 27/03/24 | 09/05/24 | - | - | - | - | - |
More events
Past sector events for Altimmune, Inc.
| 2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
| 2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
| 2024-05-15 04:01 pm | CELCUITY INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 08:00 am | IMMUNOME, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ALT Stock
- Calendar Altimmune, Inc.
